CD3 MicroBeads
human

Miltenyi Biotec

Order No. 130-050-101

Index

1. Description
   - 1.1 Principle of MACS® separation
   - 1.2 Background and product applications
   - 1.3 Reagent and instrument requirements
2. Protocol
   - 2.1 Sample preparation
   - 2.2 Magnetic labeling
   - 2.3 Magnetic separation
3. Example of a separation using CD3 MicroBeads
4. References

1. Description

Components 2 mL CD3 MicroBeads, human: MicroBeads conjugated to monoclonal anti-human CD3 antibodies (isotype: mouse IgG2a).

Size For 10^9 total cells, up to 100 separations.

Product format CD3 MicroBeads are supplied as a suspension containing stabilizer and 0.05% sodium azide.

Storage Store protected from light at 4–8 °C. Do not freeze. The expiration date is indicated on the vial label.

1.1 Principle of MACS® separation

First, the $CD3^+$ cells are magnetically labeled with CD3 MicroBeads. Then the cell suspension is loaded onto a MACS® Column which is placed in the magnetic field of a MACS Separator. The magnetically labeled $CD3^+$ cells are retained on the column. The unlabeled cells run through and this cell fraction is depleted of $CD3^+$ cells. After removal of the column from the magnetic field, the magnetically retained $CD3^+$ cells can be eluted as the positively selected cell fraction.

1.2 Background and product applications

CD3 is expressed on all T cells and is associated with the T cell receptor. 70–80% of human peripheral blood lymphocytes and 65–85% of thymocytes are $CD3^+$. The epitope recognized by CD3 MicroBeads is located on the CD3ε chain.

Examples of applications

- CD3 MicroBeads were used for the positive selection[1,2,3] or depletion[4,5] of T cells from peripheral blood, bronchial lavage, cell culture or various tissues such as lymphoid, nasal and tumor tissue.
- T cells isolated by MACS Technology have been used for various studies, e.g. on T cell cytotoxicity, T cell activation[1], HIV infectivity[2], signal transduction and surface marker expression.

1.3 Reagent and instrument requirements

- Buffer (degassed): Prepare a solution containing PBS (phosphate buffered saline) pH 7.2, 0.5% BSA and 2 mM EDTA by diluting MACS BSA Stock Solution (# 130-091-376) 1:20 with autoMACS™ Rinsing Solution (# 130-091-222). Keep buffer cold (4–8 °C).

  ▲ **Note:** EDTA can be replaced by other supplements such as anticoagulant citrate dextrose formula-A (ACD-A) or citrate phosphate dextrose (CPD). BSA can be replaced by other proteins such as human serum albumin, human serum or fetal calf serum. Buffers or media containing Ca^{2+} or Mg^{2+} are not recommended for use.

- MACS Columns and MACS Separators: $CD3^+$ cells can be enriched by using MS, LS or XS Columns (positive selection). CD3 MicroBeads can be used for depletion of $CD3^+$ cells on LD, CS or D Columns. Positive selection or depletion can also be performed by using the autoMACS Separator.

Column	max. number of labeled cells	max. number of total cells	Separator
Positive selection			
MS	10^7	2×10^8	MiniMACS, OctoMACS, VarioMACS, SuperMACS
LS	10^8	2×10^9	MidiMACS, QuadroMACS, VarioMACS, SuperMACS
XS	10^9	2×10^{10}	SuperMACS
Depletion			
LD	10^8	5×10^8	MidiMACS, QuadroMACS, VarioMACS, SuperMACS
CS	2×10^8		VarioMACS, SuperMACS
D	10^9		SuperMACS
Positive selection or depletion			
autoMACS	2×10^8	4×10^9	autoMACS

▲ **Note:** Column adapters are required to insert certain columns into VarioMACS™ Separator or SuperMACS™ Separator. For details, see MACS Separator data sheets.

- (Optional) Fluorochrome-conjugated CD3 antibody for flow-cytometric analysis, e.g. CD3-FITC (# 130-080-401), CD3-PE (# 130-091-374), or CD3-APC (# 130-091-373).
- (Optional) PI (propidium iodide) or 7-AAD for flow- cytometric exclusion of dead cells.
- (Optional) Pre-Separation Filters (# 130-041-407) to remove cell clumps.

140-000-066.05

Miltenyi Biotec GmbH
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
Phone +49 2204 8306-0, Fax +49 2204 85197
macs@miltenyibiotec.de
www.miltenyibiotec.com

Miltenyi Biotec Inc.
2303 Lindbergh Street, Auburn, CA 95602, USA
Phone 800 FOR MACS, +1 530 888 8871, Fax +1 530 888 8925
macs@miltenyibiotec.com

2. Protocol

2.1 Sample preparation

When working with anticoagulated peripheral blood or buffy coat, peripheral blood mononuclear cells (PBMCs) should be isolated by density gradient centrifugation (e.g. Ficoll-Paque™, see "General Protocols" in the User Manuals or visit www.miltenyibiotec.com/protocols).

▲ **Note:** Remove platelets after density gradient separation: resuspend cell pellet in buffer and centrifuge at 200×g for 10–15 minutes at 20 °C. Carefully remove supernatant. Repeat washing step and carefully remove supernatant.

When working with tissues, prepare a single-cell suspension by a standard preparation method (see "General Protocols" in the User Manuals or visit www.miltenyibiotec.com/protocols).

▲ **Note:** Dead cells may bind non-specifically to MACS MicroBeads. To remove dead cells, we recommend using density gradient centrifugation or the Dead Cell Removal Kit (# 130-090-101).



2.2 Magnetic labeling

▲ Work fast, keep the cells cold, and use pre-cooled solutions. This will prevent capping of antibodies on the cell surface and non-specific cell labeling.

▲ Volumes for magnetic labeling given below are for up to 10^7 total cells. When working with fewer than 10^7 cells, use the same volumes as indicated. When working with higher cell numbers, scale up all reagent volumes and total volumes accordingly (e.g. for 2×10^7 total cells, use twice the volume of all indicated reagent volumes and total volumes).

▲ For optimal performance it is important to obtain a single-cell suspension before magnetic separation. Pass cells through 30 µm nylon mesh (Pre-Separation Filters # 130-041-407) to remove cell clumps which may clog the column.

1. Determine cell number.
2. Centrifuge cell suspension at 300×g for 10 minutes. Pipette off supernatant completely.
3. Resuspend cell pellet in 80 µL of buffer per 10^7 total cells.
4. Add 20 µL of CD3 MicroBeads per 10^7 total cells.
5. Mix well and incubate for 15 minutes at 4–8 °C.

   ▲ **Note:** Working on ice may require increased incubation times. Higher temperatures and/or longer incubation times lead to non-specific cell labeling.
6. (Optional) Add staining antibodies, e.g. add 10 µL of CD3-FITC (# 130-080-401), and incubate for 5 minutes at 4–8 °C.
7. Wash cells by adding 1–2 mL of buffer per 10^7 cells and centrifuge at 300×g for 10 minutes. Pipette off supernatant completely.
8. Resuspend up to 10^8 cells in 500 µL of buffer.

   ▲ **Note:** For higher cell numbers, scale up buffer volume accordingly.

   ▲ **Note:** For depletion with LD Columns, resuspend up to 1.25×10^8 cells in 500 µL of buffer.
9. Proceed to magnetic separation (2.3).



2.3 Magnetic separation

▲ Choose an appropriate MACS Column and MACS Separator according to the number of total cells and the number of $CD3^+$ cells (see table in section 1.3).

Magnetic separation with MS or LS Columns

1. Place column in the magnetic field of a suitable MACS Separator (see "Column data sheets").
2. Prepare column by rinsing with appropriate amount of buffer:

   MS: 500 µL LS: 3 mL
3. Apply cell suspension onto the column.
4. Collect unlabeled cells which pass through and wash column with appropriate amount of buffer. Perform washing steps by adding buffer three times, each time once the column reservoir is empty.

   MS: 3×500 µL LS: 3×3 mL

   Collect total effluent. This is the unlabeled cell fraction.
5. Remove column from the separator and place it on a suitable collection tube.
6. Pipette appropriate amount of buffer onto the column. Immediately flush out fraction with the magnetically labeled cells by firmly applying the plunger supplied with the column.

   MS: 1 mL LS: 5 mL

   ▲ **Note:** To increase the purity of the magnetically labeled fraction, it can be passed over a new, freshly prepared column.

Magnetic separation with XS Columns

For instructions on the column assembly and the separation, refer to the "XS Column data sheet".

Depletion with LD Columns

1. Place LD Column in the magnetic field of a suitable MACS Separator (see "LD Column data sheet").
2. Prepare column by rinsing with 2 mL of buffer.
3. Apply cell suspension onto the column.
4. Collect unlabeled cells which pass through and wash column with 2×1 mL of buffer. Collect total effluent. This is the unlabeled cell fraction.

Depletion with CS Columns

1. Assemble CS Column and place it in the magnetic field of a suitable MACS Separator (see "CS Column data sheet").
2. Prepare column by filling and rinsing with 60 mL of buffer. Attach a 22G flow resistor to the 3-way-stopcock of the assembled column (see "CS Column data sheet").
3. Apply cell suspension onto the column.
4. Collect unlabeled cells which pass through and wash column with 30 mL buffer from the top. Collect total effluent. This is the unlabeled cell fraction.

Depletion with D Columns

For instructions on column assembly and separation, refer to the "D Column data sheet".

140-000-066.05

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for diagnostic or therapeutic use.

Magnetic separation with the autoMACS™ Separator

▲ Refer to the "autoMACS™ User Manual" for instructions on how to use the autoMACS Separator.

1. Prepare and prime autoMACS Separator.
2. Place tube containing the magnetically labeled cells in the autoMACS Separator. For a standard separation, choose following separation programs:

   Positive selection: "Possel"

   Depletion: "Depletes"

   ▲ **Note:** Program choice depends on the isolation strategy, the strength of magnetic labeling and the frequency of magnetically labeled cells. For details see autoMACS User Manual: "autoMACS Cell Separation Programs".
3. When using the program "Possel", collect positive fraction (outlet port "pos1"). This is the purified $CD3^+$ cell fraction.

   When using the program "Depletes", collect unlabeled fraction (outlet port "neg1"). This is the $CD3^-$ cell fraction.

3. Example of a separation using CD3 MicroBeads

Separation of PBMCs using CD3 MicroBeads and a MiniMACS™ Separator with an MS Column. The cells are fluorescently stained with CD3-FITC (# 130-080-401). Cell debris and dead cells were excluded from the analysis based on scatter signals and PI fluorescence.





4. References

1. Pitti, RM; Marsters, SA; Lawrence, DA; Roy, M; Kischkel, FC; Dowd, P; Huang, A; Donahue, CJ; Sherwood, SW; Baldwin, DT; Godowski, PJ; Wood, WI; Gurney, AL; Hillan, KJ; Cohen, RL; Goddard, AD; Botstein, D; Ashkenazi, A (1998) Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer. Nature 396: 699–703. [517]
2. Heath, S; Tew, J; Szakal, A; Burton, G (1995) Follicular Dendritic Cells and Human Immunodeficiency Virus Infectivity. Nature 377: 740–744. [177]
3. Lorenzen, DR; Düx, F; Wölk, U; Tsirpouchtsidis, A; Haas, G; Meyer, TF (1999) Immunoglobulin A1 Protease, an Exoenzyme of Pathogenic *Neisseriae*, Is a Potent Inducer of Proinflammatory Cytokines. J. Exp. Med.190: 1049–1058. [882]
4. Heidenreich, F; Jovin, T (1996) Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients. J. Neurol. 243: 57–62. [441]
5. Klein, U; Küppers, R; Rajewsky, K (1994) Variable Region Gene Analysis of B Cell Subsets Derived from a 4-year-old Child: Somatically Mutated Memory B Cells Accumulate in the Peripheral Blood Already at Young Age. J. Exp. Med.180: 1383–1393. [75]

Warnings

Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop.

Warranty

The products sold hereunder are warranted only to be free from defects in workmanship and material at the time of delivery to the customer. MILTENYI BIOTEC GmbH makes no warranty or representation, either expressed or implied, with respect to the fitness of a product for a particular purpose. There are no warranties, expressed or implied, which extend beyond the technical specifications of the products. MILTENYI BIOTEC GmbH's liability is limited to either replacement of the products or refund of the purchase price. MILTENYI BIOTEC GmbH is not liable for any property damage, personal injury or economic loss caused by the product.

Ficoll-Paque is a trademark of GE Healthcare companies.

MACS is a registered trademark of Miltenyi Biotec GmbH.

140-000-066.05

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for diagnostic or therapeutic use.